Deciphera Prescribed drugs, Inc. (NASDAQ:DCPH – Get Ranking) was the recipient of a major development briefly curiosity in August. As of August thirty first, there was quick curiosity totalling 7,860,000 shares, a development of 9.6% from the August fifteenth complete of seven,170,000 shares. At the moment, 16.8% of the shares of the inventory are quick offered. Based mostly on a median each day buying and selling quantity, of 934,200 shares, the short-interest ratio is presently 8.4 days.
Deciphera Prescribed drugs Inventory Efficiency
Shares of DCPH traded up $0.14 throughout mid-day buying and selling on Monday, reaching $18.61. The corporate had a buying and selling quantity of 645,794 shares, in comparison with its common quantity of 1,199,860. The corporate’s 50 day easy transferring common is $15.54 and its 200 day easy transferring common is $12.39. Deciphera Prescribed drugs has a 1-year low of $6.51 and a 1-year excessive of $20.88. The corporate has a market capitalization of $1.24 billion, a price-to-earnings ratio of -4.35 and a beta of 1.00.
Deciphera Prescribed drugs (NASDAQ:DCPH – Get Ranking) final issued its quarterly earnings knowledge on Thursday, August 4th. The corporate reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.05. The enterprise had income of $32.49 million through the quarter, in comparison with analyst estimates of $30.11 million. Deciphera Prescribed drugs had a detrimental web margin of 231.99% and a detrimental return on fairness of 74.37%. The agency’s quarterly income was up 37.8% on a year-over-year foundation. Throughout the identical quarter final 12 months, the enterprise earned ($1.21) EPS. As a gaggle, equities analysts forecast that Deciphera Prescribed drugs will publish -2.5 earnings per share for the present fiscal 12 months.
Wall Avenue Analyst Weigh In
DCPH has been the subject of plenty of analyst stories. HC Wainwright elevated their value goal on shares of Deciphera Prescribed drugs from $20.00 to $25.00 and gave the inventory a “purchase” score in a analysis be aware on Monday, September twelfth. JMP Securities upgraded shares of Deciphera Prescribed drugs from a “market carry out” score to an “outperform” score and set a $23.00 value goal on the inventory in a analysis be aware on Friday, August fifth. Piper Sandler elevated their value goal on shares of Deciphera Prescribed drugs from $13.00 to $18.00 in a analysis be aware on Sunday, September eleventh. Cowen initiated protection on shares of Deciphera Prescribed drugs in a analysis be aware on Monday, August twenty ninth. They set an “outperform” score and a $25.00 value goal on the inventory. Lastly, SVB Leerink elevated their value goal on shares of Deciphera Prescribed drugs from $21.00 to $25.00 and gave the inventory an “outperform” score in a analysis be aware on Monday, September twelfth. Two analysis analysts have rated the inventory with a promote score, 5 have given a maintain score and 5 have given a purchase score to the inventory. Based mostly on knowledge from MarketBeat.com, the corporate presently has a consensus score of “Maintain” and a median goal value of $17.90.
Institutional Inflows and Outflows
Numerous giant buyers have just lately added to or lowered their stakes within the enterprise. FMR LLC raised its holdings in Deciphera Prescribed drugs by 1.3% within the 2nd quarter. FMR LLC now owns 87,638 shares of the corporate’s inventory valued at $1,152,000 after shopping for an extra 1,102 shares over the past quarter. American Worldwide Group Inc. raised its holdings in Deciphera Prescribed drugs by 6.8% within the 2nd quarter. American Worldwide Group Inc. now owns 21,086 shares of the corporate’s inventory valued at $277,000 after shopping for an extra 1,348 shares over the past quarter. Mariner LLC raised its holdings in Deciphera Prescribed drugs by 6.6% within the 1st quarter. Mariner LLC now owns 22,472 shares of the corporate’s inventory valued at $208,000 after shopping for an extra 1,401 shares over the past quarter. Hennion & Walsh Asset Administration Inc. raised its holdings in Deciphera Prescribed drugs by 1.6% within the 2nd quarter. Hennion & Walsh Asset Administration Inc. now owns 103,235 shares of the corporate’s inventory valued at $1,358,000 after shopping for an extra 1,592 shares over the past quarter. Lastly, Ensign Peak Advisors Inc raised its holdings in Deciphera Prescribed drugs by 4.4% within the 1st quarter. Ensign Peak Advisors Inc now owns 39,850 shares of the corporate’s inventory valued at $369,000 after shopping for an extra 1,670 shares over the past quarter. Institutional buyers personal 72.29% of the corporate’s inventory.
About Deciphera Prescribed drugs
(Get Ranking)
Deciphera Prescribed drugs, Inc, a biopharmaceutical firm, develops medication to boost the lives of most cancers sufferers by addressing key mechanisms of drug resistance that restrict the speed and sturdiness of response to current most cancers therapies in america and internationally. Its lead drug candidate is QINLOCK used for the therapy of gastrointestinal stromal tumors (GIST), in addition to in INTRIGUE Part 3 research to deal with second-line GIST.
Additional Studying
This prompt information alert was generated by narrative science expertise and monetary knowledge from MarketBeat so as to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you contemplate Deciphera Prescribed drugs, you will need to hear this.
MarketBeat retains observe of Wall Avenue’s top-rated and greatest performing analysis analysts and the shares they advocate to their shoppers each day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Deciphera Prescribed drugs wasn’t on the record.
Whereas Deciphera Prescribed drugs presently has a “Maintain” score amongst analysts, top-rated analysts imagine these 5 shares are higher buys.
View The 5 Shares Right here
